StreetInsider.com News Articles

Form 8-K Crinetics Pharmaceutical For: Aug 28

Fri, 28 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260828/26998898.html

Form 8-K Crinetics Pharmaceutical For: Aug 28

Fri, 28 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260828/26998898.html

Form 4 Crinetics Pharmaceutical For: Aug 20 Filed by: Schilke Tobin

Mon, 24 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260824/26968892.html

Form 4 Crinetics Pharmaceutical For: Aug 20 Filed by: Schilke Tobin

Mon, 24 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260824/26968892.html

Form 8-K Crinetics Pharmaceutical For: Aug 19

Wed, 19 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260819/26949993.html

Form 8-K Crinetics Pharmaceutical For: Aug 19

Wed, 19 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260819/26949993.html

Form 8-K Crinetics Pharmaceutical For: Aug 12

Fri, 14 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26925172.html

Form 8-K Crinetics Pharmaceutical For: Aug 12

Fri, 14 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26925172.html

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: WELLINGTON MANAGEMENT GROUP LLP

Thu, 13 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260813/26921147.html

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: WELLINGTON MANAGEMENT GROUP LLP

Thu, 13 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260813/26921147.html

Form 4 Crinetics Pharmaceutical For: Aug 07 Filed by: Struthers Richard Scott

Tue, 11 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26905818.html

Form 4 Crinetics Pharmaceutical For: Aug 07 Filed by: Struthers Richard Scott

Tue, 11 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26905818.html

H.C. Wainwright Reiterates Neutral Rating on Crinetics (CRNX)

Tue, 11 Aug 2026 06:47:56 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Neutral rating and $85.00 price target on Crinetics (NASDAQ: CRNX).

The analyst commented: "Crinetics reported $24.0M in Palsonify net product revenue for 2Q26, up from $10.3M in 1Q26 and $5.4M in 4Q25. Total revenue was $25.1M, including $1.1M of collaboration and license revenue. The company received 245 enrollment forms in the quarter and has now had 385 unique HCPs prescribe Palsonify across the first three quarters of launch, with over 70% of patients on reimbursed therapy at quarter-end. Because of the pending Vertex (VRTX; Fein; Buy) transaction, Crinetics withdrew prior guidance and did not

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: FMR LLC

Fri, 07 Aug 2026 11:05:00 -0400

si-local-file:///var/storage/secattach/20260807/26889281.html

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: FMR LLC

Fri, 07 Aug 2026 11:05:00 -0400

si-local-file:///var/storage/secattach/20260807/26889281.html

Crinetics Pharmaceuticals (CRNX) Tops Q2 EPS by 8c

Mon, 03 Aug 2026 16:43:45 -0400

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($1.14), $0.08 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $25.12 million versus the consensus estimate of $14.87 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

Form 10-Q Crinetics Pharmaceutical For: Jun 30

Mon, 03 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260803/26857968.html

Form 10-Q Crinetics Pharmaceutical For: Jun 30

Mon, 03 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260803/26857968.html

Form 8-K Crinetics Pharmaceutical For: Aug 03

Mon, 03 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260803/26857871.html

Form 8-K Crinetics Pharmaceutical For: Aug 03

Mon, 03 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260803/26857871.html

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mon, 03 Aug 2026 16:05:00 -0400

Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired

PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the second quarter ended June

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mon, 03 Aug 2026 16:05:00 -0400

Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired

PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mon, 03 Aug 2026 16:05:00 -0400

Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired

PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mon, 03 Aug 2026 16:05:00 -0400

Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired

PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026

Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Mon, 03 Aug 2026 08:29:00 -0400

si-local-file:///var/storage/secattach/20260803/26854412.html